CONTEXT: Lymphomas involving the breast are rare, and most cases are of B-cell lineage; T-cell neoplasms represent less than 10% of all breast lymphomas. OBJECTIVE: To define the clinicopathologic spectrum of anaplastic large cell lymphomas (ALCLs) involving the breast. DESIGN: Six cases of ALCL involving the breast were identified at a single institution during 21 years. The clinicopathologic and immunophenotypic features are presented, and the literature is reviewed. RESULTS: All patients were women, with a median age of 52 years. There were 4 anaplastic lymphoma kinase- negative (ALK(-)) ALCL cases; 3 of these neoplasms developed around breast implants. Two patients with ALK(-) ALCL had a history of cutaneous ALCL. There were 2 ALK(+) ALCLs; both patients had stage IV disease. Histologically, all neoplasms were composed of large anaplastic cells that were uniformly CD30(+) and expressed markers of T-cell lineage. Four patients with adequate follow-up are alive, with a mean of 4.1 years (range, 1.5-9 years) after diagnosis of the breast tumor. Included in this group are 2 patients with ALK(-) ALCL associated with breast implants who were alive 4 years and 9 years after diagnosis. CONCLUSIONS: Including the 6 cases we describe, a total of 21 cases of ALCL involving the breast are reported. Fifteen cases, all ALK(-), were associated with breast implants, suggesting a possible pathogenetic relationship, and associated with an excellent prognosis. Patients with cutaneous ALCL can subsequently develop ALK(-) ALCL involving the breast, and these tumors can be associated with breast implants.
CONTEXT: Lymphomas involving the breast are rare, and most cases are of B-cell lineage; T-cell neoplasms represent less than 10% of all breast lymphomas. OBJECTIVE: To define the clinicopathologic spectrum of anaplastic large cell lymphomas (ALCLs) involving the breast. DESIGN: Six cases of ALCL involving the breast were identified at a single institution during 21 years. The clinicopathologic and immunophenotypic features are presented, and the literature is reviewed. RESULTS: All patients were women, with a median age of 52 years. There were 4 anaplastic lymphoma kinase- negative (ALK(-)) ALCL cases; 3 of these neoplasms developed around breast implants. Two patients with ALK(-) ALCL had a history of cutaneous ALCL. There were 2 ALK(+) ALCLs; both patients had stage IV disease. Histologically, all neoplasms were composed of large anaplastic cells that were uniformly CD30(+) and expressed markers of T-cell lineage. Four patients with adequate follow-up are alive, with a mean of 4.1 years (range, 1.5-9 years) after diagnosis of the breast tumor. Included in this group are 2 patients with ALK(-) ALCL associated with breast implants who were alive 4 years and 9 years after diagnosis. CONCLUSIONS: Including the 6 cases we describe, a total of 21 cases of ALCL involving the breast are reported. Fifteen cases, all ALK(-), were associated with breast implants, suggesting a possible pathogenetic relationship, and associated with an excellent prognosis. Patients with cutaneous ALCL can subsequently develop ALK(-) ALCL involving the breast, and these tumors can be associated with breast implants.
Authors: Tessa L St Cyr; Barbara A Pockaj; Donald W Northfelt; Fiona E Craig; Mark W Clemens; Raman C Mahabir Journal: Plast Surg (Oakv) Date: 2020-05-21 Impact factor: 0.947
Authors: Mark W Clemens; L Jeffrey Medeiros; Charles E Butler; Kelly K Hunt; Michelle A Fanale; Steven Horwitz; Dennis D Weisenburger; Jun Liu; Elizabeth A Morgan; Rashmi Kanagal-Shamanna; Vinita Parkash; Jing Ning; Aliyah R Sohani; Judith A Ferry; Neha Mehta-Shah; Ahmed Dogan; Hui Liu; Nora Thormann; Arianna Di Napoli; Arianna DiNapoli; Stephen Lade; Jorge Piccolini; Ruben Reyes; Travis Williams; Colleen M McCarthy; Summer E Hanson; Loretta J Nastoupil; Rakesh Gaur; Yasuhiro Oki; Ken H Young; Roberto N Miranda Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Roberto N Miranda; Tariq N Aladily; H Miles Prince; Rashmi Kanagal-Shamanna; Daphne de Jong; Luis E Fayad; Mitual B Amin; Nisreen Haideri; Govind Bhagat; Glen S Brooks; David A Shifrin; Dennis P O'Malley; Chan Y Cheah; Carlos E Bacchi; Gabriela Gualco; Shiyong Li; John A Keech; Ephram P Hochberg; Matthew J Carty; Summer E Hanson; Eid Mustafa; Steven Sanchez; John T Manning; Zijun Y Xu-Monette; Alonso R Miranda; Patricia Fox; Roland L Bassett; Jorge J Castillo; Brady E Beltran; Jan Paul de Boer; Zaher Chakhachiro; Dongjiu Ye; Douglas Clark; Ken H Young; L Jeffrey Medeiros Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544